Your session is about to expire
← Back to Search
Chemotherapy + Bevacizumab for Non-Small Cell Lung Cancer
Study Summary
This trial is comparing chemotherapy with or without bevacizumab in treating patients with early stage non-small cell lung cancer.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2015 Phase 4 trial • 45 Patients • NCT02036424Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- Your SGPT (ALT) level in the blood is less than 5 times the upper limit of normal.I had surgery to remove my lung cancer, which was not a minor procedure, and had specific lymph nodes checked.Your total bilirubin level must be less than or equal to 1.5 mg/dL.I haven't had hormone or radiation cancer treatments in the last 5 years.Your prothrombin time/international normalized ratio (INR) should be 1.5 or less.My blood clotting time is within the normal range, or if I'm on blood thinners, it's not more than 1.5 times the upper limit.I am not currently coughing up a significant amount of bright red blood.I have had heart issues but have been symptom-free for over a year.You must have a certain amount of a type of white blood cell called neutrophils in your blood.Women who could become pregnant must take a blood or urine test to make sure they are not pregnant before joining the study.I haven't had any cancer in the last 5 years, except for cervical in-situ carcinoma or non-melanoma skin cancer that was fully removed.I am not pregnant or breastfeeding.My blood pressure is under control and below 150/90.I am on a stable blood thinner regimen or using it for DVT prevention.I am taking aspirin or NSAIDs daily, but not dipyridamole, ticlopine, clopidogrel, or cilostazol.I am eligible for pemetrexed/cisplatin therapy.My lung cancer is not of the squamous cell type.My kidney function is good, as shown by recent tests.My blood clotting time is within safe limits while on blood thinners.Your SGOT (AST) levels are not more than 5 times the upper limit of normal.I had lung surgery between 6 to 12 weeks ago and have recovered well.Your kidney function, as measured by a blood test for creatinine, is within a certain range.I haven't had any major abdominal issues like a fistula, perforation, or abscess in the last month.I am not expecting to undergo any major surgeries during the study.I am fully active or restricted in physically strenuous activity but can do light work.I have never had a stroke or a mini-stroke.My urine protein levels are low enough for me to join.I have never had chemotherapy, except possibly low-dose methotrexate for a non-cancer condition.I haven't had major surgery, serious injuries, or biopsies recently.I don't have any serious infections, heart issues, or other conditions that would stop me from following the study's requirements.I have never had bleeding disorders.You are allergic to Chinese hamster ovary cell products or other similar medicines made from living cells.Your platelet count must be at least 100,000 per cubic millimeter.
- Group 1: Arm I (chemotherapy)
- Group 2: Arm II (chemotherapy, bevacizumab)
- Pivotal Trial - The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Could you please detail the side effects of Bevacizumab?
"Bevacizumab has been studied in multiple Phase 3 trials, so there is some data to support its efficacy and safety."
For what purpose is Bevacizumab commonly prescribed?
"Bevacizumab, which is most often used to treat cervical cancer that has come back, can also be used to treat other conditions like non-small cell lung cancer, metastatic bladder cancer, and directives that are in place in advance."
Could you list some other studies that have used Bevacizumab in the past?
"In 1997, City of Hope Comprehensive Cancer Center first studied bevacizumab. Since then, a total of 3939 completed trials. Data suggests that there are currently 1727 actively recruiting studies, many of which are based in Indianapolis, Indiana."
Can people with the qualifying illness still enroll in the research program?
"The clinical trial in question is not currently looking for new patients, as evidenced by its last update on October 18th, 2022. However, there are 5474 other clinical trials that are still recruiting patients."
How many study participants will be chosen in total?
"Unfortunately, this particular trial is no longer recruiting patients. Although, it was last updated on October 18th, 2022, so it may become active again in the future. There are 3747 other trials related to carcinoma and 1727 trials involving Bevacizumab that are actively recruiting patients."
Who else is applying?
What site did they apply to?
What portion of applicants met pre-screening criteria?
Share this study with friends
Copy Link
Messenger